UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

A cancer survivor from Horsham is feeling the effect of a life- changing treatment that has now been approved on the NHS.

US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene ...